Dihydroquinoline-2-one derivatives

1. A compound according to formula (I),

wherein:

R 1 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 2 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 3 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 4 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R 3 and R 4 together with the carbon atoms to which they are attached form a double bond;

R 5 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 6 is H or R 8 ;

R 7 is H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R 1 and R 7 together with the nitrogen and carbon atoms to which they are attached form a heterocycloalkyl substituted with one to three substituents independently selected from H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 8 is —O m —(CR 9 R 10 ) n —(C 11 R 12 ) p —(CR 13 R 14 ) q —NR 15 R 16 ,

—N m R 17 —(CR 9 R 10 ) n —(CR 11 R 12 ) p —(CR 13 R 14 ) q —NR 15 R 16 or

—S m (O) r —(CR 9 R 10 ) n —(CR 11 R 12 ) p —(CR 13 R 14 ) q —NR 15 R 16 ;

R 9 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 10 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 11 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R 10 and R 11 together with the carbon atoms to which they are attached form a double bond;

R 12 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R 11 and R 12 together with the carbon atom to which they are attached form a cycloalkyl or a heterocycloalkyl;

R 13 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 14 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

or R 10 and R 14 together form —(CH 2 ) t —;

R 15 is H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl or hydroxyalkyl;

R 16 is H, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, phenylalkyl, substituted phenylalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, —S(O) 2 R 18 , —S(O)R 18 , —S(O) 2 OR 18 , —S(O) 2 NR 18 R 19 , —C(O)R 18 , —C(O)OR 18 or —C(O)NR 18 R 19 , wherein substituted phenylalkyl, substituted aryl, substituted heterocycloalkyl and substituted heteroaryl are substituted with one to three substituents independently selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl, halocycloalkylalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxycarbonyl, halogen, hydroxy, oxo, cyano, triazolylalkyl, tetrazolylalkyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, aminocarbonyl, substituted aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylcarbonylaminoalkyl and cycloalkylcarbonylaminoalkyl, wherein substituted amino, substituted aminoalkyl and substituted aminocarbonyl are substituted on the nitrogen atom with one to two substituents independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl, wherein in case R 15 is H or alkyl and R 16 is H or alkyl, then the sum of n, p and q is at least 1;

or R 15 and R 16 together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, wherein substituted heterocycloalkyl and substituted heteroaryl are substituted with R 23 , R 24 and R 25 ;

or R 13 and R 15 together with the nitrogen and carbon atoms to which they are attached form a substituted heterocycloalkyl, wherein substituted heterocycloalkyl is substituted with R 23 , R 24 and R 25 ;

or R 11 and R 15 together with the nitrogen and carbon atoms to which they are attached form a substituted heterocycloalkyl, wherein substituted heterocycloalkyl is substituted with R 23 , R 24 and R 25 ;

or R 9 and R 15 together with the nitrogen and carbon atoms to which they are attached form a substituted heterocycloalkyl, wherein substituted heterocycloalkyl is substituted with R 23 , R 24 and R 25 ;

R 17 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 18 is alkyl, cycloalkyl, haloalkyl, halocycloalkyl, hydroxyalkyl, halohydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, alkylcarbonyloxyalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, wherein substituted aryl, substituted heterocycloalkyl and substituted heteroaryl are substituted with one to three substituents independently selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl, halocycloalkylalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxycarbonyl, halogen, hydroxy, oxo, cyano, triazolylalkyl, tetrazolylalkyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, aminocarbonyl, substituted aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylcarbonylaminoalkyl and cycloalkylcarbonylaminoalkyl, wherein substituted amino, substituted aminoalkyl and substituted aminocarbonyl are substituted on the nitrogen atom with one to two substituents independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl;

R 19 is H, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

A 1 is CR 20 ;

A 2 is CR 21 or N;

A 3 is CR 22 ;

R 20 is H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 21 is H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 22 is H, halogen, alkyl, haloalkyl, cycloalkyl or halocycloalkyl;

R 23 , R 24 and R 25 are each independently selected from H, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, alkylcycloalkyl, halocycloalkyl, alkylcycloalkylalkyl, halocycloalkylalkyl, cycloalkylalkyl, cycloalkylalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkylalkoxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, haloalkoxyalkyl, alkoxyalkoxy, alkoxyalkoxyalkyl, alkoxycarbonyl, —S(O) 2 R 18 ,

—C(O)R 18 , halogen, hydroxy, oxo, cyano, triazolylalkyl, tetrazolylalkyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, aminocarbonyl, substituted aminocarbonyl, alkylcarbonylamino, cycloalkylcarbonylamino, alkylcarbonylaminoalkyl and cycloalkylcarbonylaminoalkyl, wherein substituted amino, substituted aminoalkyl and substituted aminocarbonyl are substituted on the nitrogen atom with one to two substituents independently selected from alkyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, alkylcycloalkylalkyl, hydroxyalkyl and alkoxyalkyl;

wherein in case m is zero and R 9 and R 15 , or R 11 and R 15 or R 13 and R 15 or R 15 and R 16 together with the nitrogen and carbon atoms to which they are attached form a substituted heterocycloalkyl or a substituted heteroaryl, then at least one of R 23 , R 24 , R 25 and R 16 is different from H, alkyl, haloalkyl, alkoxy, haloalkoxy, halogen, hydroxy, cyano, amino, substituted amino, aminocarbonyl, substituted aminocarbonyl, wherein substituted amino and substituted aminocarbonyl are substituted on the nitrogen atom with one to two alkyl, and —C(O)R 18 , —S(O) 2 R 18 , wherein R 18 is alkyl, haloalkyl, hydroxyalkyl, halohydroxyalkyl, alkoxyalkyl or haloalkoxyalkyl;

m is zero or 1, wherein in case m is 1, then the sum of n and p is 2, 3 or 4;

n is zero, 1 or 2;

p is zero, 1 or 2;

q is zero, 1 or 2;

r is zero, 1 or 2, wherein in case m is zero then r is zero; and

t is zero, 1 or 2;

or a pharmaceutically acceptable salt or ester thereof.

2. The compound according to claim 1 , wherein R 1 is H or alkyl.

3. The compound according to claim 1 , wherein R 2 is H.

4. The compound according to claim 1 , wherein R 3 is H.

5. The compound according to claim 1 , wherein R 4 is H or alkyl.

6. The compound according to claim 1 , wherein R 5 is H or alkyl.

7. The compound according to claim 1 , wherein R 7 is H.

8. The compound according to claim 1 , wherein is R 8 is —O m —(CR 9 R 10 ) n —(CR 11 R 12 ) p —(CR 13 R 14 ) q —NR 15 R 16 .

9. The compound according to claim 1 , wherein R 9 is H, alkyl or cycloalkyl.

10. The compound according to claim 1 , wherein R 10 is H or alkyl.

11. The compound according to claim 1 , wherein R 11 is H.

12. The compound according to claim 1 , wherein R 12 is H.

13. The compound according to claim 1 , wherein R 13 is H.

14. The compound according to claim 1 , wherein R 14 is H.

15. The compound according to claim 1 , wherein R 15 is H, alkyl or alkoxyalkyl.

16. The compound according to claim 1 , wherein R 9 and R 15 together with the nitrogen and carbon atoms to which they are attached form a substituted heterocycloalkyl, wherein substituted heterocycloalkyl is substituted with R 23 , R 24 and R 25 .

17. The compound according to claim 1 , wherein R 16 is H, hydroxyalkyl, phenylalkyl, heterocycloalkyl substituted with alkyl, —S(O)R 18 , —S(O) 2 R 18 , —C(O)R 18 or —C(O)OR 18 , wherein in case R 15 is H or alkyl and R 16 is H or alkyl, then the sum of n, p and q is at least 1.

18. The compound according to a claim 1 , wherein R 16 is hydroxyalkyl, —S(O) 2 R 18 , —C(O)R 18 or —C(O)OR 18 .

19. The compound according to claim 1 , wherein R 15 and R 16 together with the nitrogen atom to which they are attached form a substituted heterocycloalkyl wherein substituted heterocycloalkyl is substituted with one to three substituents independently selected from hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxycarbonyl, oxo, triazolylalkyl and substituted aminoalkyl, wherein substituted aminoalkyl is substituted on the nitrogen atom with one to two alkyl.

20. The compound according to claim 1 , wherein R 18 is alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkylcarbonyloxyalkyl, aryl, substituted aryl, heterocycloalkyl, substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, wherein substituted aryl, substituted heterocycloalkyl and substituted heteroaryl are substituted with one to three substituents independently selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl and halogen.

21. The compound according to claim 1 , wherein R 23 , R 24 and R 25 are each independently selected from hydrogen, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxyalkyl, alkoxycarbonyl, oxo, triazolylalkyl and substituted aminoalkyl, wherein substituted aminoalkyl is substituted on the nitrogen atom with one to two alkyl.

22. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-amide;

Acetic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylcarbamoyl]-methyl ester;

2-Hydroxy-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-acetamide;

6-[5-(2-Hydroxy-ethylamino)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((R)-2-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-5-oxo-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Ethylaminomethyl-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Methoxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

1-Methyl-6-[5-((S)-2-[1,2,4]triazol-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

6-(5-Benzylamino-pyridin-3-yl)-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-5-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

1-Methyl-6-[5-(2-oxo-pyrrolidin-1-yl)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one, and

Ethanesulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable salts thereof.

23. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [5-(1,4,4-trimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-(2-oxo-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

1-Methyl-6-[5-(2-oxo-piperidin-1-ylmethyl)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

6-[5-(1,1-Dioxo-1λ 6 -thiomorpholin-4-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[S—((S)-2-Methoxymethyl-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

(S)-1-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-pyrrolidine-2-carboxylic acid methyl ester;

1-Methyl-6-{5-[(S)-2-(2,2,2-trifluoro-ethoxymethyl)-pyrrolidin-1-ylmethyl]-pyridin-3-yl}-3,4-dihydro-1H-quinolin-2-one;

6-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester; and

6-[S—((R)-1-Hydroxymethyl-2-methyl-propylamino)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

24. The compound according to claim 1 , selected from the group consisting of:

6-[6-((R)-1-Hydroxymethyl-2-methyl-propylamino)-pyrazin-2-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-(5-Aminomethyl-pyridin-3-yl)-1-methyl-3,4-dihydro-1H-quinolin-2-one;

N-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-propionamide;

Propane-2-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

{2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxyl]-ethyl}-carbamic acid tert-butyl ester;

3-Methoxy-isoxazole-5-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Cyclopropanecarboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-[5-(2-Amino-ethoxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

N-{2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-propionamide; and

6-[5-(1,1-Dioxo-1λ 6 -[1,2]thiazinan-2-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

25. The compound according to claim 1 , selected from the group consisting of:

(S)-2-(5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxymethyl)-azetidine-1H-carboxylic acid tert-butyl ester;

(R)-3-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid tert-butyl ester;

3-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-azetidine-1-carboxylic acid tert-butyl ester;

(S)-3-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid tert-butyl ester;

(S)-3-[5-(1-Methyl-2-oxo-1,2,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-piperidine-1-carboxylic acid tert-butyl ester;

4-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-piperidine-1-carboxylic acid tert-butyl ester;

(S)-2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester;

(S)-3-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid tert-butyl ester;

(R)-3-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid tert-butyl ester;

(R)-2-Methyl-propane-2-sulfinic acid {3-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-oxetan-3-yl}-amide;

Ethanesulfonic acid [5-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

(R)-2-Methyl-propane-2-sulfinic acid {(S or R)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

(R) 2-Methyl-propane-2-sulfinic acid {(R or S)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

{(trans)-4-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl}-carbamic acid tert-butyl ester; and

6-[5-(1-Amino-cyclopropyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

26. The compound according to claim 1 , selected from the group consisting of:

1-Methyl-6-[5-((S)-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

1-Methyl-6-[5-((S)-piperidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

1-Methyl-6-[5(piperidin-4-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-((S)-1-Azetidin-2-ylmethoxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S or R)-1-Amino-ethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-((R or S)-1-Amino-ethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

1-Methyl-6-[5-((S)-1-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

7-Fluoro-1-methyl-6-[5-((R)-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

1-Methyl-6-[5-((R)-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-(3-Amino-oxetan-3-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-(Azetidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-((trans)-4-Amino-cyclohexyloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-(1-Amino-1-methyl-ethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-(5-Aminomethyl-pyridin-3-yl)-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one; and

6-{6-[6-(3-Methoxy-isoxazole-5-carbonyl)-2,6-diaza-spiro[3,3]hept-2-yl]-pyrazin-2-yl}-1-methyl-3,4-dihydro-1H-quinolin-2-one:

and pharmaceutically acceptable salts thereof.

27. The compound according to claim 1 , selected from the group consisting of:

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-[5-((S)-1-Cyclopropanecarbonyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

3-Methyl-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-butyramide;

3,3,3-Trifluoro-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-propionamide;

2-Hydroxy-2-methyl-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-propionamide;

5-Methyl-[1,3,4]oxadiazole-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-((S)-1-propionyl-piperidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

2-Methoxy-pyrimidine-5-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide,

1-Methyl-1H-imidazole-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Trifluoromethyl-furan-3-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Pyridazine-3-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Pyrimidine-5-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-1H-pyrazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-(1-propionyl-piperidin-4-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one; and

Pyridazine-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable salts thereof.

28. The compound according to claim 1 , selected from the group consisting of:

1-Methyl-6-[5-((S)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-1-Cyclopropanecarbonyl-azetidin-2-ylmethoxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

3-Methyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

4-Fluoro-2,6-dimethyl-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-benzamide;

1-Methyl-6-[5-((S)-1-propionyl-azetidin-2-ylmethoxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

3,6-Dichloro-pyridazine-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Cyclopropyl-1-(2,2,2-trifluoro-ethyl)-1H-pyrazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1,3-Dimethyl-1H-pyrazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Pyrimidine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-Methoxy-pyridazine-3-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Methyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

1 Methyl-1H-pyrazole-4-carboxylic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide; and

6-Chloro-pyridazine-3-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable salts thereof.

29. The compound according to claim 1 , selected from the group consisting of:

3-Chloro-6-methyl-pyridazine-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-((S)-1-propionyl-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

5-Cyclopropyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrabydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

2-Methyl-5-trifluoromethyl-oxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

2-Methyl-oxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Cyclopropyl-oxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

2,5-Dimethyl-oxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Methyl-oxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

6-Chloro-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Methyl-pyridine-2-carboxylic acid [5(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,6-Dichloro-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-Methyl-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

3-Fluoro-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable salts thereof.

30. The compound according to claim 1 , selected from the group consisting of:

5-Chloro-3-methyl-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-((R)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

7-Fluoro-1-methyl-6-[5-((S)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

5-Trifluoromethyl-pyrimidine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Methyl-pyrazine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Chloro-pyrazine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

5-Trifluoromethyl-pyrazine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-((R)-1-propionyl-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

1-Methyl-6-[5-(1I-propionyl-azetidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

N-3-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-oxetan-3-yl)-propionamide;

3-Chloro-pyridine-2-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,6-Dichloro-pyridazine-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

7-Fluoro-1-methyl-6-[5-((R)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

5-Chloro-3-methoxy-pyrazine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

3,5-Dimethyl-isoxazole-4-carboxylic acid {(R or S)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

and pharmaceutically acceptable salts thereof.

31. The compound according to claim 1 , selected from the group consisting of:

3-Methyl-5-trifluoromethyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

3-Chloro-pyridine-2-carboxylic acid {1-methyl-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {1-methyl-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid {1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

3-Methyl-pyridine-2-carboxylic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

N-{(trans)-4-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl}-propionamide;

5-Trifluoromethyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

7-Fluoro-1-methyl-6-[5-((S)-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

(R)-2-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester;

1-Methyl-6-[5-((R)-1-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-(5-Aminomethyl-pyridin-3-yl)-3,4-dihydro-1H-quinolin-2-one; and

6-[5-(1-Amino-cyclopropyl)-pyridin-3-yl]-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

32. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

3-Chloro-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-benzenesulfonamide;

6-Methoxy-pyridin-3-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Cyclopropanesulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,4-Dichloro-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-benzenesulfonamide;

1-Methyl-1H-imidazole-4-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-Chloro-pyridine-3-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-1H-pyrazole-4-sulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-[5-((S)-1-Ethanesulfonyl-piperidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-(1-Ethanesulfonyl-piperidin-4-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

2,2,2-Trifluoro-ethanesulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

C,C,C-Trifluoro-N-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methanesulfonamide;

6-[5-((S)-1-Ethanesulfonyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one; and

6-[5-((S)-1-Ethanesulfonyl-azetidin-2-ylmethoxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one:

and pharmaceutically acceptable salts thereof.

33. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

6-[5-((S)-1-Ethanesulfonyl-pyrrolidin-2-ylmethoxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((R)-1-Ethanesulfonyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one:

6-[5-((R)-1-Ethanesulfonyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-(1-Ethanesulfonyl-azetidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one,

Ethanesulfonic acid {1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

Ethanesulfonic acid {(trans)-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl}-amide;

Ethanesulfonic acid {(R or S)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid {(S or R)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

1-Methyl-1H-pyrazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

(rac)-Ethanesulfonic acid {2-methyl-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-propyl}-amide;

(rac)-Ethanesulfonic acid {cyclopropyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-methyl}-amide;

(rac)-Ethanesulfonic acid {1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

6-[5-(1,1-Dioxo-1λ6-isothiazolidin-2-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one; and

(rac)-Ethanesulfonic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-propyl}-amide;

and pharmaceutically acceptable salts thereof.

34. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid ethyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid methyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid {1-methyl-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid isopropyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid (2-ethoxy-ethyl)-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

(rac)-Ethanesulfonic acid methyl-{1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

(rac)-Ethanesulfonic acid ethyl-{1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid methyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-{5-[2-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-ethoxy]-pyridin-3-yl}-1-methyl-3,4-dihydro-1H-quinolin-2-one;

Ethanesulfonic acid {(R or S)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid {(S or R)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

Ethanesulfonic acid methyl-{2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

and pharmaceutically acceptable salts thereof.

35. The compound according to claim 1 , selected from the group consisting of:

3-Chloro-pyridine-2-carboxylic acid methyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

N-Methyl-N-{2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-propionamide;

1-Methyl-1H-pyrazole-4-carboxylic acid methyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Methyl-pyridine-2-carboxylic acid methyl-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrabydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methyl-amide;

3-Chloro-pyridine-2-carboxylic acid methyl-{1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

1-Methyl-1H-pyrazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methyl-amide;

Ethanesulfonic acid [5-(8-chloro-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(8-chloro-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(8-chloro-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-{5-[(3-Ethyl-oxetan-3-ylamino)-methyl]-pyridin-3-yl}-1-methyl-3,4-dihydro-1H-quinolin-2-one;

Ethanesulfonic acid [5-(7-chloro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [5-(8-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [5-(8-chloro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

Ethanesulfonic acid [5-(5-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable salts thereof.

36. The compound according to claim 1 , selected from the group consisting of:

Ethanesulfonic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methyl-amide;

N-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-propionamide;

(rac)-N-{1-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-propionamide;

(S)-3-[5-(2-Oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid tert-butyl ester;

3-Chloro-pyridine-2-carboxylic acid methyl-[5-(2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(8-chloro-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methyl-amide;

(R)-2-Methyl-propane-2-sulfinic acid [4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

6-(5-Aminomethyl-4-chloro-pyridin-3-yl)-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

3,5-Dimethyl-isoxazole-4-carboxylic acid [4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

(R)-2-Methyl-propane-2-sulfinic acid [4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]1-amide;

6-(5-Aminomethyl-4-methyl-pyridin-3-yl)-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

3,5-Dimethyl-isoxazole-4-carboxylic acid [4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

(R)-2-Methyl-propane-2-sulfinic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

and pharmaceutically acceptable suits thereof.

37. The compound according to claim 1 , selected from the group consisting of:

6-(5-Aminomethyl-4-methyl-pyridin-3-yl)-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

3-Chloro-pyridine-2-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-methyl-amide;

3-Chloro-pyridine-2-carboxylic acid methyl-[4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid {(R or S)-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

5′-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-5,6-dihydro-4H-[3,3′]bipyridinyl-1-carboxylic acid tert-butyl ester;

{2-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-carbamic acid tert-butyl ester;

3-Chloro-pyridine-2-carboxylic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

Ethanesulfonic acid [5-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [5-(3-oxo-2,3,6,7-tetrabydro-1H,5H-pyrido[3,2,1-ij]quinolin-9-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid methyl-[5-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-pyridin-3-ylmethyl]-amide;

6-[5-(2-Amino-ethoxy)-pyridin-3-yl]-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

(R)-2-Methyl-propane-2-sulfinic acid {(R or S)-1-[4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide; and

6-[5-((R or S)-1-Amino-ethyl)-4-methyl-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

and pharmaceutically acceptable salts thereof.

38. The compound according to claim 1 , selected from the group consisting of:

3-Chloro-pyridine-2-carboxylic acid {(R or S)-1-[4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {(R or S)-1-[4-methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

3-Chloro-pyridine-2-carboxylic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

N-(trans)-4-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl)-methanesulfonamide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3′,6′-dihydro-2′H-[3,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester;

Ethanesulfonic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-methyl-amide;

(R)-2-Methyl-propane-2-sulfinic acid {(R or S)-1-[4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrabydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

6-[5-(R or S)-1-Amino-ethyl)-4-chloro-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

3-Chloro-pyridine-2-carboxylic acid {(R or S)-1-[4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

(R)-2-Methyl-propane-2-sulfinic acid {(R or S)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-yl]-ethyl}-amide;

6-[5-((R or S)-1-Amino-ethyl)-4-methyl-pyridin-3-yl]-7-fluoro-1-methyl-3,4-dihydro-1H-quinolin-2-one hydrochloride;

6-[5-((S)-1-Acetyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one; and

1-Methyl-6-{5-[(S)-1-(1-methyl-1H-pyrazole-4-carbonyl)-pyrrolidin-3-yloxy]-pyridin-3-yl}-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

39. The compound according to claim 1 , selected from the group consisting of:

(S)-3-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-pyrrolidine-1-carboxylic acid ethyl ester;

3,5-Dimethyl-isoxazole-4-carboxylic acid {(R or S)-1-[4-chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3-Chloro-pyridine-2-carboxylic acid {(R or S)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-yl]-ethyl}-amide;

5-Methyl-isoxazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,34-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3′,4′,5′,6′-tetrahydro-2′H-[3,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester;

N-{(R or S)-1-[4-Chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-propionamide;

6-[5-(1-Amino-cyclopropyl)-pyridin-3-yl]-1-methyl-1H-quinolin-2-one;

Ethanesulfonic acid [5-(8-fluoro-1-methyl-2-oxo-1,2-dihydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

N-{(R or S)-1-[5-(7-Fluoro-1-methyl-2-oxo-1,2,3,4-tetrabydro-quinolin-6-yl)-4-methyl-pyridin-3-yl]-ethyl}-propionamide;

N-[4-Chloro-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-propionamide;

N-{(R or S)-1-[4-Methyl-5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-propionamide; and

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

and pharmaceutically acceptable salts thereof.

40. The compound according to claim 1 selected from the group consisting of:

6-[5-(2-Hydroxy-ethylamino)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-pyrrolidin-1-yl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

6-[5-((S)-2-Hydroxymethyl-5-oxo-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

Ethanesulfonic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide; and

1-Methyl-6-[5-(2-oxo-pyrrolidin-1-ylmethyl)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

6-[5-((R)-1-Hydroxymethyl-2-methyl-propylamino)-pyridin-3-yl]-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

41. The compound according to claim 1 selected from the group consisting of:

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

1-Methyl-6-[5-((S)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

5-Methyl-isoxazole-4-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

1-Methyl-1H-pyrazole-4-carboxylic acid {2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

3-Chloro-pyridine-2-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

7-Fluoro-1-methyl-6-[5-((R)-1-propionyl-pyrrolidin-3-yloxy)-pyridin-3-yl]-3,4-dihydro-1H-quinolin-2-one;

3-Chloro-pyridine-2-carboxylic acid {1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

3-Chloro-pyridine-2-carboxylic acid {1-methyl-1-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

3-Chloro-pyridine-2-carboxylic acid {1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-cyclopropyl}-amide;

Ethanesulfonic acid {(trans)-4-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl}-amide;

1-Methyl-1H-pyrazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-ylmethyl]-amide;

Ethanesulfonic acid {1-methyl-1-[5(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide; and

6-{5-[2-(1,1-Dioxo-1λ6-isothiazolidin-2-yl)-ethoxy]-pyridin-3-yl}-1-methyl-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

42. The compound according to claim 1 selected from the group consisting of: Ethanesulfonic acid {(R or S)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid {(S or R)-1-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yl]-ethyl}-amide;

Ethanesulfonic acid methyl-{2-[5-(1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide;

Ethanesulfonic acid [5-(4-oxo-1,2,5,6-tetrahydro-4H-pyrrolo[3,2,1-ij]quinolin-8-yl)-pyridin-3-ylmethyl]-amide;

N-{(trans)-4-[5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-cyclohexyl}-methanesulfonamide;

3,5-Dimethyl-isoxazole-4-carboxylic acid [5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-4-methyl-pyridin-3-ylmethyl]-amide;

5-(1-Methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-3′,6′-dihydro-2′H-[3,4′]bipyridinyl-1′-carboxylic acid tert-butyl ester;

Ethanesulfonic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-methyl-amide;

3,5-Dimethyl-isoxazole-4-carboxylic acid {2-[5-(7-fluoro-1-methyl-2-oxo-1,2,3,4-tetrahydro-quinolin-6-yl)-pyridin-3-yloxy]-ethyl}-amide; and

1-Methyl-6-{5-[(S)-1-(1-methyl-1H-pyrazole-4-carbonyl)-pyrrolidin-3-yloxy]-pyridin-3-yl}-3,4-dihydro-1H-quinolin-2-one;

and pharmaceutically acceptable salts thereof.

43. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.